MiNK Therapeutics, Inc.

1.00 USD
-0.04 (-3.87%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

MiNK Therapeutics, Inc. stock is down -14.55% since 30 days ago. The next earnings date is Mar 19, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 December’s closed higher than November.

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate, AGENT-797, is in Phase 1 clinical trials.